Brivaracetam to Treat Partial Onset Seizures in Adults

# Purpose of Review Seizures are a hyperexcitable, and hypersynchronous imbalance between excitatory and inhibitory factors (E/I imbalance) in neurotransmission, and epilepsy is the recurrent manifestation of seizures within a reasonable time frame and without being attributable to a reversible cau...

Full description

Bibliographic Details
Main Authors: Dustin Latimer, David Le, Evan Falgoust, Patrick Ingraffia, Alaa Abd-Elsayed, Elyse M. Cornett, Rupin Singh, JooHee Choi, Giustino Varrassi, Adam M. Kaye, Alan D. Kaye, Latha Ganti
Format: Article
Language:English
Published: Open Medical Publishing 2023-01-01
Series:Health Psychology Research
Online Access:https://doi.org/10.52965/001c.56782
_version_ 1797341635050209280
author Dustin Latimer
David Le
Evan Falgoust
Patrick Ingraffia
Alaa Abd-Elsayed
Elyse M. Cornett
Rupin Singh
JooHee Choi
Giustino Varrassi
Adam M. Kaye
Alan D. Kaye
Latha Ganti
author_facet Dustin Latimer
David Le
Evan Falgoust
Patrick Ingraffia
Alaa Abd-Elsayed
Elyse M. Cornett
Rupin Singh
JooHee Choi
Giustino Varrassi
Adam M. Kaye
Alan D. Kaye
Latha Ganti
author_sort Dustin Latimer
collection DOAJ
description # Purpose of Review Seizures are a hyperexcitable, and hypersynchronous imbalance between excitatory and inhibitory factors (E/I imbalance) in neurotransmission, and epilepsy is the recurrent manifestation of seizures within a reasonable time frame and without being attributable to a reversible cause. Brivaracetam is a derivative of the antiepileptic agent, levetiracetam, that is used as adjuvant therapy for focal onset seizures. It was approved by the FDA in 2016 and has shown promising results with minimal adverse effect reactions in clinical trials. # Recent Findings Brivaracetam has been used in multiple clinical trials at various dosages in adults that have partial-onset seizures refractory to conventional treatment. A meta-analysis in 2016 showed that brivaracetam as adjunctive therapy was statically significant in its reduction of adults with drug-refractory seizure frequency.^1^ The most commonly reported adverse effects that patients who were taking brivaracetam experienced were somnolence, headache, and dizziness. Further studies are necessary to conclude long term efficacy and safety profile of brivaracetam. # Conclusion The treatment of epilepsy with pharmacologic agents is a difficult task due to balancing the efficacy of the drug with the side effect profile that will allow for the best quality of life for the patient. There are approximately 30 antiepileptic agents for clinicians to choose from. Brivaracetam is a novel antiepileptic agent that was approved for use by the FDA in 2016 and is showing promising results as monotherapy and adjunctive therapy in individuals with drug-refractory focal seizures while minimizing adverse drug reactions.
first_indexed 2024-03-08T10:20:50Z
format Article
id doaj.art-a1f248dd9137472d8d47e587386dc7f8
institution Directory Open Access Journal
issn 2420-8124
language English
last_indexed 2024-03-08T10:20:50Z
publishDate 2023-01-01
publisher Open Medical Publishing
record_format Article
series Health Psychology Research
spelling doaj.art-a1f248dd9137472d8d47e587386dc7f82024-01-27T23:14:29ZengOpen Medical PublishingHealth Psychology Research2420-81242023-01-01105Brivaracetam to Treat Partial Onset Seizures in AdultsDustin LatimerDavid LeEvan FalgoustPatrick IngraffiaAlaa Abd-ElsayedElyse M. CornettRupin SinghJooHee ChoiGiustino VarrassiAdam M. KayeAlan D. KayeLatha Ganti# Purpose of Review Seizures are a hyperexcitable, and hypersynchronous imbalance between excitatory and inhibitory factors (E/I imbalance) in neurotransmission, and epilepsy is the recurrent manifestation of seizures within a reasonable time frame and without being attributable to a reversible cause. Brivaracetam is a derivative of the antiepileptic agent, levetiracetam, that is used as adjuvant therapy for focal onset seizures. It was approved by the FDA in 2016 and has shown promising results with minimal adverse effect reactions in clinical trials. # Recent Findings Brivaracetam has been used in multiple clinical trials at various dosages in adults that have partial-onset seizures refractory to conventional treatment. A meta-analysis in 2016 showed that brivaracetam as adjunctive therapy was statically significant in its reduction of adults with drug-refractory seizure frequency.^1^ The most commonly reported adverse effects that patients who were taking brivaracetam experienced were somnolence, headache, and dizziness. Further studies are necessary to conclude long term efficacy and safety profile of brivaracetam. # Conclusion The treatment of epilepsy with pharmacologic agents is a difficult task due to balancing the efficacy of the drug with the side effect profile that will allow for the best quality of life for the patient. There are approximately 30 antiepileptic agents for clinicians to choose from. Brivaracetam is a novel antiepileptic agent that was approved for use by the FDA in 2016 and is showing promising results as monotherapy and adjunctive therapy in individuals with drug-refractory focal seizures while minimizing adverse drug reactions.https://doi.org/10.52965/001c.56782
spellingShingle Dustin Latimer
David Le
Evan Falgoust
Patrick Ingraffia
Alaa Abd-Elsayed
Elyse M. Cornett
Rupin Singh
JooHee Choi
Giustino Varrassi
Adam M. Kaye
Alan D. Kaye
Latha Ganti
Brivaracetam to Treat Partial Onset Seizures in Adults
Health Psychology Research
title Brivaracetam to Treat Partial Onset Seizures in Adults
title_full Brivaracetam to Treat Partial Onset Seizures in Adults
title_fullStr Brivaracetam to Treat Partial Onset Seizures in Adults
title_full_unstemmed Brivaracetam to Treat Partial Onset Seizures in Adults
title_short Brivaracetam to Treat Partial Onset Seizures in Adults
title_sort brivaracetam to treat partial onset seizures in adults
url https://doi.org/10.52965/001c.56782
work_keys_str_mv AT dustinlatimer brivaracetamtotreatpartialonsetseizuresinadults
AT davidle brivaracetamtotreatpartialonsetseizuresinadults
AT evanfalgoust brivaracetamtotreatpartialonsetseizuresinadults
AT patrickingraffia brivaracetamtotreatpartialonsetseizuresinadults
AT alaaabdelsayed brivaracetamtotreatpartialonsetseizuresinadults
AT elysemcornett brivaracetamtotreatpartialonsetseizuresinadults
AT rupinsingh brivaracetamtotreatpartialonsetseizuresinadults
AT jooheechoi brivaracetamtotreatpartialonsetseizuresinadults
AT giustinovarrassi brivaracetamtotreatpartialonsetseizuresinadults
AT adammkaye brivaracetamtotreatpartialonsetseizuresinadults
AT alandkaye brivaracetamtotreatpartialonsetseizuresinadults
AT lathaganti brivaracetamtotreatpartialonsetseizuresinadults